Neuronal PAS domain protein 3 (NPAS3) is a member of the basic helix-loop-helix (bHLH) family of transcription factors. It contains a bHLH domain involved in DNA binding, a PAS domain (acronym derived from the three initial proteins in which this motif was found) that alters the affinity for binding-partners in response to cellular signaling, and a transcriptional activation domain.
1 bHLH transcription factors regulate multiple processes, including neurogenesis, metabolism and circadian rhythms. 2, 3 Population studies have associated common genetic variations of NPAS3 with schizophrenia, 4 bipolar disorder 5 and antipsychotic efficacy. 6 Two nonsynonymous substitutions (A522P and A742V) have been previously associated with schizophrenia, 7 and a balanced (9:14) translocation that disrupts NPAS3 was detected in a small family in which the translocation segregates with schizophrenia. 8 Like the effect of the 1:11 translocation on DISC1, the translocation through NPAS3 may result in a loss of gene and protein expression, or it could produce a truncated NPAS3 protein with a dominant negative effect. Both possibilities imply a loss of NPAS3 function.
We have identified a novel mutation in NPAS3 that segregates with mental illness in a small Caucasian US family. Thirty-four probands (26 with schizophrenia, 8 with schizoaffective disorders) from a large genetic study of US pedigrees 9 were selected for sequencing based on extensive family loading for schizophrenia (a sib with schizophrenia or schizoaffective disorder, and an additional first degree (N ¼ 26) or second degree (N ¼ 8) family member with schizophrenia, schizoaffective disorder, bipolar disorder, schizotypal personality disorder or psychotic disorder NOS). NPAS3 exons and 3 0 and 5 0 flanking regions were sequenced using PCR and capillary electrophoresis (ABI 3730). We detected a G to A mutation in exon 8 at bp 910 (c.910 G4A) in a proband with schizophrenia ( Figure 1a ). The mutation results in a valine to isoleucine coding change at amino acid 304 (Figures 1b and c). We obtained DNA from all available family members, and sequenced PCR products of the region to establish the presence of the mutation. The mother and a sib of the proband with schizophrenia have the mutation, as does a young sib (age 20 at ascertainment) with major depression. The father with schizotypal personality disorder and a sister with major depression (age 30 at ascertainment), do not have the mutation (Figure 1d) . Unfortunately, the family is unavailable for a reassessment of phenotype or a search for more family members.
We used an allele-specific real-time PCR assay to screen for the mutation in 600 probands with schizophrenia and 600 controls from the NIMH Genetics Initiative. The mutation was not detected in either affected or unaffected individuals. The mutation (rs146677388) was detected in 2 of 2184 genomes (both of African-American individuals) examined in the 1000 Genome Project (MAF ¼ 0.09%).
The segregation of V304I with psychiatric disease in the small US family is intriguing. The family is too small to reach a definitive conclusion about the etiologic role of NPAS3-V304I, and detection of the mutation in two individuals of unknown phenotype does not exclude an etiologic role. Nonetheless, the biological effects of valine to isoleucine mutations in amyloid precursor protein 10 and transthyretin, 11 and the location of the mutation in a region likely related to DNA binding capacity and protein stability, 12 support an etiologic role for NPAS3-V304I. We therefore attempted to determine if the mutation changes NPAS3 function. Constructs consisting of GFP, full length NPAS3 complementary DNA, or full length NPAS3-V304I cDNA were cloned into the pCMV6 mammalian expression vector and demonstrated to have comparable expression levels by western blotting (data not shown). These constructs were transfected into mouse primary neurons at in vitro day 2 (2 DIV) such that cells expressed GFP, GFP and NPAS3 or GFP and NPAS3-V304I. Cells were imaged and assayed for neurite outgrowth. There was a significant decrease in neurite outgrowth with NPAS3-V304I compared with GFP or GFP plus NPAS3 (Figure 1e and f), supporting our hypothesis of the biological relevance of V304I.
We recognize that overexpression of a protein does not reflect a normal physiological state, and only provides a limited model of endogenous protein function. However, neurite outgrowth has been shown to be a sensitive measure of neuronal perturbation used to determine the potential relevance of other genes linked to schizophrenia, including DISC1. 13 Therefore, a difference in neurite outgrowth between NPAS3 and NPAS3-V304I provides evidence for a functional role of the mutation.
Identification of NPAS3-V304I helps strengthen the hypothesis that NPAS3 is involved in schizophrenia pathogenesis. Searching for other NPAS3 mutations, exploring the relationship between NPAS3 variation and human brain structure and function, and developing animal models of NPAS3 variants will further define the functional properties of normal and variant NPAS3 and possibly provide insights into the pathogenesis of schizophrenia and related illnesses.
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